Qianjiang Yongan Pharmaceutical Co., Ltd.
Символ: 002365.SZ
SHZ
7.13
CNYПазарна цена днес
-173.0390
Съотношение P/E
-2.8428
Коефициент PEG
2.10B
MRK Cap
- 0.01%
Доходност на DIV
Qianjiang Yongan Pharmaceutical Co., Ltd. (002365-SZ) финансови отчети
Баланс
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 3614.43 | 956.5 | 832.2 | 547.5 | ||||||||||||||||||
balance-sheet.row.short-term-investments | 2540.18 | 630.4 | 557.5 | 454 | ||||||||||||||||||
balance-sheet.row.net-receivables | 822.61 | 178.4 | 203.1 | 367.8 | ||||||||||||||||||
balance-sheet.row.inventory | 390.1 | 69.9 | 149.6 | 145.8 | ||||||||||||||||||
balance-sheet.row.other-current-assets | 17.63 | 8.8 | 10.4 | 4.8 | ||||||||||||||||||
balance-sheet.row.total-current-assets | 4844.77 | 1213.6 | 1195.3 | 1065.9 | ||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 4022.12 | 970.9 | 1023.5 | 989.3 | ||||||||||||||||||
balance-sheet.row.goodwill | 26.82 | 0.5 | 8.8 | 8.8 | ||||||||||||||||||
balance-sheet.row.intangible-assets | 333.36 | 82.4 | 84.5 | 87.9 | ||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 360.18 | 82.9 | 93.3 | 96.7 | ||||||||||||||||||
balance-sheet.row.long-term-investments | -1535.76 | 68.3 | -476.1 | -338.8 | ||||||||||||||||||
balance-sheet.row.tax-assets | 39.5 | 11.3 | 9.7 | 9.9 | ||||||||||||||||||
balance-sheet.row.other-non-current-assets | 1927.34 | 0.1 | 578.5 | 462.9 | ||||||||||||||||||
balance-sheet.row.total-non-current-assets | 4813.39 | 1133.5 | 1228.8 | 1220 | ||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-assets | 9658.15 | 2347.1 | 2424.2 | 2285.9 | ||||||||||||||||||
balance-sheet.row.account-payables | 619.84 | 128.8 | 162.8 | 114.9 | ||||||||||||||||||
balance-sheet.row.short-term-debt | 77.31 | 47.3 | 40 | 20.4 | ||||||||||||||||||
balance-sheet.row.tax-payables | 40.56 | 7.8 | 4.9 | 5.5 | ||||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0 | 0 | ||||||||||||||||||
Deferred Revenue Non Current | 37.81 | 8.5 | 11.3 | 13.1 | ||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 116.46 | - | - | - | ||||||||||||||||||
balance-sheet.row.other-current-liab | 157.42 | 65.6 | 70.6 | 78.5 | ||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 145.77 | 33.1 | 36 | 35.6 | ||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-liab | 1225.91 | 290.3 | 321.2 | 328.9 | ||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.common-stock | 1178.73 | 294.7 | 294.7 | 294.7 | ||||||||||||||||||
balance-sheet.row.retained-earnings | 3434.7 | 812.7 | 854.5 | 728.2 | ||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 2072.55 | 163.8 | 155.4 | 130.9 | ||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 1425.56 | 712.8 | 712.8 | 712.2 | ||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 8111.53 | 1983.9 | 2017.4 | 1865.9 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 9658.15 | 2347.1 | 2424.2 | 2285.9 | ||||||||||||||||||
balance-sheet.row.minority-interest | 312.21 | 64.4 | 85.6 | 91.1 | ||||||||||||||||||
balance-sheet.row.total-equity | 8423.74 | 2048.3 | 2103 | 1957 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 9658.15 | - | - | - | ||||||||||||||||||
Total Investments | 1004.42 | 698.7 | 81.4 | 115.2 | ||||||||||||||||||
balance-sheet.row.total-debt | 77.31 | 47.3 | 40 | 20.4 | ||||||||||||||||||
balance-sheet.row.net-debt | -996.95 | -278.9 | -234.7 | -73.1 |
Отчет за паричните потоци
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -12.31 | -12.3 | 132.7 | 119 | ||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 33.88 | 135.2 | 123.6 | 116 | ||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 6.8 | 2.4 | -3.8 | ||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | -176.9 | 0.9 | 12.4 | ||||||||||||||||||
cash-flows.row.change-in-working-capital | 106.58 | 93.5 | 99.1 | -152.4 | ||||||||||||||||||
cash-flows.row.account-receivables | 18.85 | 18.9 | 163.2 | -172.1 | ||||||||||||||||||
cash-flows.row.inventory | 87.73 | 87.7 | -10 | -63.7 | ||||||||||||||||||
cash-flows.row.account-payables | 0 | -13.1 | -56.5 | 87.2 | ||||||||||||||||||
cash-flows.row.other-working-capital | 0 | 0 | 2.4 | -3.8 | ||||||||||||||||||
cash-flows.row.other-non-cash-items | 66.4 | 197.9 | 28.5 | 10.7 | ||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 194.56 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -120.74 | -120.7 | -149.1 | -63 | ||||||||||||||||||
cash-flows.row.acquisitions-net | 0.95 | 1 | 0.4 | -35.9 | ||||||||||||||||||
cash-flows.row.purchases-of-investments | -1484.2 | -1484.2 | -1110.7 | -823.2 | ||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 1409.01 | 1392.7 | 1029 | 943.5 | ||||||||||||||||||
cash-flows.row.other-investing-activites | 45.21 | 45.2 | 0 | 0.5 | ||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -149.77 | -166 | -230.4 | 21.8 | ||||||||||||||||||
cash-flows.row.debt-repayment | -40 | -30 | -40 | -132.3 | ||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.dividends-paid | -38.61 | -29.5 | -1.6 | -30.7 | ||||||||||||||||||
cash-flows.row.other-financing-activites | 3.74 | -6.3 | 59.4 | 23.8 | ||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -65.77 | -65.8 | 17.8 | -139.2 | ||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 7.08 | 7.1 | 6.5 | -1.1 | ||||||||||||||||||
cash-flows.row.net-change-in-cash | 21.27 | 51.5 | 181.2 | -16.7 | ||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 1031.05 | 326.2 | 274.7 | 93.5 | ||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 1009.78 | 274.7 | 93.5 | 110.2 | ||||||||||||||||||
cash-flows.row.operating-cash-flow | 194.56 | 244.3 | 387.3 | 101.8 | ||||||||||||||||||
cash-flows.row.capital-expenditure | -120.74 | -120.7 | -149.1 | -63 | ||||||||||||||||||
cash-flows.row.free-cash-flow | 73.81 | 123.5 | 238.2 | 38.8 |
Ред за отчет за приходите
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 970.06 | 962.8 | 1462.4 | 1565.4 | ||||||||||||||||||
income-statement-row.row.cost-of-revenue | 723.81 | 733.5 | 980.8 | 1206.9 | ||||||||||||||||||
income-statement-row.row.gross-profit | 246.25 | 229.3 | 481.7 | 358.5 | ||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||
income-statement-row.row.research-development | 40.95 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-general-administrative | 85.78 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 54.5 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-expenses | -94.08 | -1.2 | 66.2 | 69.7 | ||||||||||||||||||
income-statement-row.row.operating-expenses | 329.09 | 205 | 320.3 | 228.6 | ||||||||||||||||||
income-statement-row.row.cost-and-expenses | 1052.91 | 938.5 | 1301.1 | 1435.4 | ||||||||||||||||||
income-statement-row.row.interest-income | 1.88 | 1.9 | 0.3 | 0.2 | ||||||||||||||||||
income-statement-row.row.interest-expense | 0.37 | 0.4 | 0.7 | 2.4 | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 54.5 | - | - | - | ||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 49.22 | -20.9 | 0.7 | -1.8 | ||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-operating-expenses | -94.08 | -1.2 | 66.2 | 69.7 | ||||||||||||||||||
income-statement-row.row.total-operating-expenses | 49.22 | -20.9 | 0.7 | -1.8 | ||||||||||||||||||
income-statement-row.row.interest-expense | 0.37 | 0.4 | 0.7 | 2.4 | ||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 15.71 | 135.2 | 167.1 | 132.3 | ||||||||||||||||||
income-statement-row.row.ebitda-caps | -28.62 | - | - | - | ||||||||||||||||||
income-statement-row.row.operating-income | -44.32 | 24.3 | 152.4 | 131.7 | ||||||||||||||||||
income-statement-row.row.income-before-tax | 4.9 | 3.4 | 153.1 | 129.9 | ||||||||||||||||||
income-statement-row.row.income-tax-expense | 34.47 | 34.5 | 20.3 | 10.8 | ||||||||||||||||||
income-statement-row.row.net-income | -12.31 | -12.3 | 140.3 | 111.4 |
Често задавани въпроси
Какво е Qianjiang Yongan Pharmaceutical Co., Ltd. (002365.SZ) общи активи?
Qianjiang Yongan Pharmaceutical Co., Ltd. (002365.SZ) общите активи са 2347138093.000.
Какъв е годишният приход на предприятието?
Годишните приходи са 391624730.000.
Какъв е маржът на печалбата на предприятието?
Маржът на печалбата на фирмата е 0.250.
Какъв е свободният паричен поток на компанията?
Свободният паричен поток е 0.250.
Какъв е маржът на нетната печалба на предприятието?
Маржът на нетната печалба е -0.013.
Какъв е общият приход на предприятието?
Общият приход е -0.046.
Каква е Qianjiang Yongan Pharmaceutical Co., Ltd. (002365.SZ) нетна печалба (нетен доход)?
Нетната печалба (нетният доход) е -12312563.000.
Какъв е общият дълг на фирмата?
Общият дълг е 47305897.000.
Какъв е броят на оперативните разходи?
Оперативните разходи са 205002116.000.
Какъв е броят на паричните средства на фирмата?
Паричните средства на предприятието са 326171803.000.